Education

  • Brandeis University (B.A., 1988, 
    magna cum laude)
  • University of Pennsylvania School of Law (J.D., 1991, cum laude, Order of the Coif)

Admissions

  • District of Columbia and New York
  • United States Courts of Appeals for the District of Columbia Circuit, and the Fourth Circuit
  • United States District Court for the District of Columbia

Opinions

Neil S. Bromberg’s practice focuses on the overall defense of serial, mass tort, and other complex litigation matters, with a particular emphasis on defending – and trying – pharmaceutical products liability litigation.  On behalf of Firm client Novartis Pharmaceuticals Corporation, Mr. Bromberg recently managed the defense of 142 cases as part of a consolidated litigation in New Jersey involving claims that Novartis’s bisphosphonate drugs used in cancer therapies cause a "signature disease" known as osteonecrosis of the jaw ("ONJ"). He secured a 7-1 defense verdict for Novartis in the second bellwether case chosen for trial in the New Jersey litigation over the drugs Aredia® and Zometa®.  Meng v. Novartis Pharm. Corp., No. MID-L-7670-07-MT (N.J. Super. Ct. Law Div. May 15, 2013).  After deliberating for fewer than six hours, the Meng jury rejected the plaintiff’s failure-to-warn claim.  Prior to that decisive victory, Mr. Bromberg won the first bellwether trial in the New Jersey consolidated litigation in 2010.  Bessemer v. Novartis Pharm. Corp., MID-L-1835-08-MT (N.J. Super. Ct. Law Div. Oct. 22, 2010).

Mr. Bromberg has significant experience defending and deposing expert witnesses in various fields, including oncology, oral surgery, neurology, obstetrics, pharmacology, and internal medicine.  This experience extends beyond the deposition stage, where he specializes in designing and implementing strategies to exclude (or limit) expert testimony through motions practice or evidentiary hearings pursuant to DaubertKemp, and similar admissibility standards.

Mr. Bromberg has extensive toxic tort experience, having previously represented gasoline manufacturers in personal injury and wrongful death litigation involving alleged exposure to benzene.

Mr. Bromberg has spoken at public and private seminars on a variety of issues including e-discovery and scientific evidence.  He is a past co-chair of the Mealey’s Benzene Litigation Conference.  He previously served on the Steering Committee and was the Internet Coordinator of the Litigation Section of the Bar Association for the District of Columbia, and was also Chair of the Publications Committee and Vice Chair of the Programs Committee.  Additionally, he has served as a member of the Continuing Legal Education Committee of the D.C. Bar's Board of Governors.

Mr. Bromberg was nominated to run for the position of D.C. Representative to the ABA House of Delegates in 2001.  In 2006, he served as an appellate judge for the American Bar Association's National Appellate Advocacy Competition.  Mr. Bromberg is a member of the Defense Research Institute.

What's
Hot

Bloomberg BNA: Monsanto: Cancer Study Suppression is ‘Scientific Vandalism’

Hollingsworth LLP represents Monsanto in In Re:Roundup Products Liability Litigation in the Northern District of California.